文献速递骨质疏松与代谢性骨病

2型糖尿病主要骨质疏松性骨折预测:一项衍生与比较研究

Major osteoporosis fracture prediction in type 2 diabetes: a derivation and comparison study.
PubMed 文献 · Osteoporos Int · 2022-05-18

该回顾性队列研究纳入1730例2型糖尿病患者,开发了中国糖尿病骨折风险(CDFR)模型并与FRAX比较。中位随访10年间6.3%发生主要骨质疏松性骨折,CDFR模型包含8个预测因子,C统计量为0.803,校准良好;未调整FRAX低估骨折风险,CDFR判别与校准均优于FRAX。

要点

  • CDFR模型含年龄、性别、既往骨折、胰岛素使用、糖尿病周围神经病变等8个预测因子。
  • CDFR的C统计量为0.803(95%CI 0.761-0.844),校准χ2为4.63(p=0.86)。
  • 未调整FRAX低估MOF风险,观察/预测比为2.62(95%CI 2.17-3.08)。

核心结论

  • CDFR模型对2型糖尿病患者的10年主要骨质疏松性骨折风险预测性能良好,尤其在胰岛素使用或糖尿病周围神经病变患者中。
  • 未来需要在外部队列中验证该模型。

研究设计与样本

  • 回顾性队列研究,纳入2009年8月至2013年7月期间的1730例2型糖尿病患者。
  • 通过电子健康记录和电话访谈收集随访期间的主要骨质疏松性骨折。
  • 采用多因素Cox回归结合向后逐步法拟合模型,从判别和校准方面比较CDFR、FRAX及调整FRAX的性能。

主要发现

  • 中位随访10年期间,6.3%的参与者发生主要骨质疏松性骨折。
  • 最终CDFR模型包含8个预测因子:年龄、性别、既往骨折、胰岛素使用、糖尿病周围神经病变、总胆固醇、甘油三酯和载脂蛋白A。
  • CDFR模型的C统计量为0.803(95%CI 0.761-0.844),校准χ2为4.63(p=0.86)。
  • 未调整FRAX低估MOF风险(校准χ2 134.5,p<0.001;观察/预测比2.62,95%CI 2.17-3.08),糖尿病调整后仍存在显著低估。
  • 与FRAX相比,CDFR具有更高的AUC、更低的校准χ2和更好的MOF重分类。

关键数值与推荐

  • CDFR模型包含8个预测因子:年龄、性别、既往骨折、胰岛素使用、糖尿病周围神经病变、总胆固醇、甘油三酯和载脂蛋白A。
  • CDFR的C统计量为0.803(95%CI 0.761-0.844),校准χ2为4.63(p=0.86)。
  • 未调整FRAX的校准χ2为134.5(p<0.001),观察/预测比为2.62(95%CI 2.17-3.08)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 未来需要在外部队列中验证该模型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The widely recommended fracture prediction tool FRAX was developed based on and for the general population. Although several adjusted FRAX methods were suggested for type 2 diabetes (T2DM), they still need to be evaluated in T2DM cohort. INTRODUCTION: This study was undertaken to develop a prediction model for Chinese diabetes fracture risk (CDFR) and compare its performance with those of FRAX. METHODS: In this retrospective cohort study, 1730 patients with T2DM were enrolled from 2009.08 to 2013.07. Major osteoporotic fractures (MOFs) during follow-up were collected from Electronic Health Records (EHRs) and telephone interviews. Multivariate Cox regression with backward stepwise selection was used to fit the model. The performances of the CDFR model, FRAX, and adjusted FRAX were compared in the aspects of discrimination and calibration. RESULTS: 6.3% of participants experienced MOF during a median follow-up of 10 years. The final model (CDFR) included 8 predictors: age, gender, previous fracture, insulin use, diabetic peripheral neuropathy (DPN), total cholesterol, triglycerides, and apolipoprotein A. This model had a C statistic of 0.803 (95%CI 0.761-0.844) and calibration χ2 of 4.63 (p = 0.86). The unadjusted FRAX underestimated the MOF risk (calibration χ2 134.5, p < 0.001; observed/predicted ratio 2.62, 95%CI 2.17-3.08), and there was still significant underestimation after diabetes adjustments. Comparing FRAX, the CDFR had a higher AUC, lower calibration χ2, and better reclassification of MOF. CONCLUSION: The CDFR model has good performance in 10-year MOF risk prediction in T2DM, especially in patients with insulin use or DPN. Future work is needed to validate our model in external cohort(s).

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Kong XK, Zhao ZY, Zhang D, et al. Major osteoporosis fracture prediction in type 2 diabetes: a derivation and comparison study. Osteoporos Int. 2022. PMID: 35583602. doi:10.1007/s00198-022-06425-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。